A Phase 1 interventional study of [177Lu]Lu-ABY-271 in Metastatic Breast Cancer and HER2 + Breast Cancer, sponsored by Affibody. Recruiting at 3 sites in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by Affibody · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Breast Neoplasms with a site in Sweden — 56 open to participants now, 91 under way, 31 of them phase 3. Breast Neoplasms · Sweden.
Among the 252 studies in Breast Neoplasms with a site in Sweden, this one is the 200th largest by planned enrollment of the 209 interventional ones that give a count, is one of 17 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 45 of the 90 other live ones, and was the 240th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →56 of the 252 studies in Breast Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden, Finland, Korea, Republic of
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+ · Women only
Region Jönköping County · Sites in Sweden
Ages 70+
Harokopio University · Sites in Sweden, Greece, Lithuania and 1 more country
Ages 18+ · Women only · Healthy volunteers
Delcath Systems Inc. · Sites in Sweden, United States, Italy and 1 more country
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 58 · Phase 3 88 · Phase 4 2
First in 1977; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 330 across the 209 interventional studies, 567 across the 42 observational. Of the 145 that completed or were terminated, 69 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 252 have an industry lead sponsor. The 10 most frequent:
Affibody is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Affibody has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
19 of the studies in Breast Neoplasms with a site in Sweden that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04722692Phase 3Uppsala UniversityDelayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ | 2026-12-30 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
Add all 19 to your calendar (.ics) → With an account.
Among the 252 studies in Breast Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.
The trial consists of two parts:
Part A in which the uptake of [177Lu]Lu-ABY-271 in tumors and critical organs will be evaluated and up to 6 subjects will be enrolled sequentially.
Part B in which the optimal protein mass dose range (mg) to be utilized in subsequent clinical trials will be evaluated. 15 subjects will be randomized to 3 different protein mass dose levels (1:1:1), divided into two sequential cohorts with different radioactivity levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A only
- Subject is in treatment, or planned to start a new line of standard systemic anti-tumor therapy
Part B only
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\[177Lu\]Lu-ABY-271
Drug: [177Lu]Lu-ABY-271
\[177Lu\]Lu-ABY-271 with protein mass dose A
Drug: [177Lu]Lu-ABY-271
\[177Lu\]Lu-ABY-271 with protein mass dose B
Drug: [177Lu]Lu-ABY-271
\[177Lu\]Lu-ABY-271 with Protein mass dose C
Drug: [177Lu]Lu-ABY-271
A single infusion of \[177Lu\]Lu-ABY-271
Treatment emergent adverse events
Time frame: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43
Dose Limiting Toxicities
Time frame: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43
Absorbed dose in gray (Gy) per organ and selected tumors
Time frame: From baseline to day 8
Absorbed dose coefficient (Gy/GBq) per organ and selected tumors
Time frame: From baseline to day 8
Normalized whole-body effective dose (millisieverts [mSv]/MBq)
Time frame: From baseline to day 8
Start is estimated for Oct 2025; primary completion for Jan 2027, 14 months later.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 14 months is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutetium-177
Affibody